Tags

Type your tag names separated by a space and hit enter

Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
Eur J Clin Microbiol Infect Dis. 2021 Mar; 40(3):485-494.EJ

Abstract

Whether antibody levels measured by commercially available enzyme or chemiluminescent immunoassays targeting the SARS-CoV-2 spike (S) protein can act as a proxy for serum neutralizing activity remains to be established for many of these assays. We evaluated the degree of correlation between neutralizing antibodies (NtAb) binding the SARS-CoV-2 spike (S) protein and SARS-CoV-2-S-IgG levels measured by four commercial immunoassays in sera drawn from hospitalized COVID-19 patients. Ninety sera from 51 hospitalized COVID-19 patients were tested by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG, and the COVID-19 ELISA IgG assays. Overall, the results obtained with the COVID-19 ELISA IgG test showed the highest agreement with the NtAb assay (κ, 0.85; 95% CI, 0.63-1). The most sensitive tests were the pseudotyped virus NtAb assay and the COVID-19 ELISA IgG assay (92.2% for both). Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (rho = 0.73) and moderate for the remaining assays (rho = 0.48 to 0.59). The kinetic profile of serum NtAb50 titers could not be reliably predicted by any of the SARS-CoV-2 IgG immunoassays. The suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms.

Authors+Show Affiliations

Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibáñez 17, 46010, Valencia, Spain.Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibáñez 17, 46010, Valencia, Spain.Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibáñez 17, 46010, Valencia, Spain.Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. david.navarro@uv.es. Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibáñez 17, 46010, Valencia, Spain. david.navarro@uv.es.

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article

Language

eng

PubMed ID

33404891

Citation

Valdivia, Arantxa, et al. "Inference of SARS-CoV-2 Spike-binding Neutralizing Antibody Titers in Sera From Hospitalized COVID-19 Patients By Using Commercial Enzyme and Chemiluminescent Immunoassays." European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, vol. 40, no. 3, 2021, pp. 485-494.
Valdivia A, Torres I, Latorre V, et al. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Eur J Clin Microbiol Infect Dis. 2021;40(3):485-494.
Valdivia, A., Torres, I., Latorre, V., Francés-Gómez, C., Albert, E., Gozalbo-Rovira, R., Alcaraz, M. J., Buesa, J., Rodríguez-Díaz, J., Geller, R., & Navarro, D. (2021). Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 40(3), 485-494. https://doi.org/10.1007/s10096-020-04128-8
Valdivia A, et al. Inference of SARS-CoV-2 Spike-binding Neutralizing Antibody Titers in Sera From Hospitalized COVID-19 Patients By Using Commercial Enzyme and Chemiluminescent Immunoassays. Eur J Clin Microbiol Infect Dis. 2021;40(3):485-494. PubMed PMID: 33404891.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. AU - Valdivia,Arantxa, AU - Torres,Ignacio, AU - Latorre,Víctor, AU - Francés-Gómez,Clara, AU - Albert,Eliseo, AU - Gozalbo-Rovira,Roberto, AU - Alcaraz,María Jesús, AU - Buesa,Javier, AU - Rodríguez-Díaz,Jesús, AU - Geller,Ron, AU - Navarro,David, Y1 - 2021/01/06/ PY - 2020/09/16/received PY - 2020/12/13/accepted PY - 2021/1/7/pubmed PY - 2021/2/26/medline PY - 2021/1/6/entrez KW - COVID-19 KW - Chemiluminescent immunoassays KW - Enzyme-linked immunosorbent assay KW - Neutralizing antibodies KW - SARS-CoV-2 SP - 485 EP - 494 JF - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology JO - Eur J Clin Microbiol Infect Dis VL - 40 IS - 3 N2 - Whether antibody levels measured by commercially available enzyme or chemiluminescent immunoassays targeting the SARS-CoV-2 spike (S) protein can act as a proxy for serum neutralizing activity remains to be established for many of these assays. We evaluated the degree of correlation between neutralizing antibodies (NtAb) binding the SARS-CoV-2 spike (S) protein and SARS-CoV-2-S-IgG levels measured by four commercial immunoassays in sera drawn from hospitalized COVID-19 patients. Ninety sera from 51 hospitalized COVID-19 patients were tested by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG, and the COVID-19 ELISA IgG assays. Overall, the results obtained with the COVID-19 ELISA IgG test showed the highest agreement with the NtAb assay (κ, 0.85; 95% CI, 0.63-1). The most sensitive tests were the pseudotyped virus NtAb assay and the COVID-19 ELISA IgG assay (92.2% for both). Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (rho = 0.73) and moderate for the remaining assays (rho = 0.48 to 0.59). The kinetic profile of serum NtAb50 titers could not be reliably predicted by any of the SARS-CoV-2 IgG immunoassays. The suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms. SN - 1435-4373 UR - https://www.unboundmedicine.com/medline/citation/33404891/Inference_of_SARS_CoV_2_spike_binding_neutralizing_antibody_titers_in_sera_from_hospitalized_COVID_19_patients_by_using_commercial_enzyme_and_chemiluminescent_immunoassays_ L2 - https://dx.doi.org/10.1007/s10096-020-04128-8 DB - PRIME DP - Unbound Medicine ER -